Judges rescues NH data in First Amendment rule

Share this article:
A New Hampshire law barring the commercial use of prescription data has been struck down on First Amendment grounds.

A federal judge agreed with the arguments of IMS Health and Verispan, which sued to block the law, dubbed the Prescription Privacy Protection Act. The law, which took effect last August, was aimed at keeping prescription data out of the hands of pharma manufacturers and crippling detailing efforts.

US District Judge Paul Barbadoro said: “Because the Prescription Information Law restricts constitutionally protected speech without directly serving the state’s substantial interests and because alternatives exist that would achieve the state’s interests as well or better without restricting speech, the law cannot be enforced to the extent that it purports to restrict the transfer or use of prescriber-identifiable data.”

The decision could forestall a gathering wave of state-level legislation aimed at stymieing drug reps by restricting companies’ access to data.

John Kamp, executive director of the Coalition for Healthcare Communication said the judge in the case “appropriately focused on the fact that the New Hampshire legislature wanted to reduce the sale of branded drugs.”

Kamp added the case was not only about New Hampshire but it was also about “New Hampshire wannabes” in other jurisdictions.

“The overturning of the New Hampshire law throws ice on top of any other state, including the federal government,” looking to enact look-alike bills, Kamp said.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.